Product Images Releuko

This text appears to be describing the before and after use of a syringe with a clear safety guard and a gray needle. The syringe has markings on the barrel and a plunger with a stopper at the top edge. After use, the gray needle is used and the clear safety cap is extended over the plunger rod.*

This appears to be a list of body parts: Upper arm (listed twice), stomach area (also referred to as the abdomen), buttocks, and thigh. It is likely a reference to areas that can be targeted or treated for exercise, weight loss, or medical purposes.*

This is a description of a medical product. The product contains 10 Single-Dose Prefilled Syringes with a Needle Guard. The product has a National Drug Code (NDC) of 70121-1568-7. Each syringe contains 300 mcg filgrastim-ayow. It is an injection with a sodium hydroxide and sorbitol solution in water. The product is manufactured by Amneal Pharmaceuticals LLC. The recommended dosage of the product can be found in the prescribing information.*

This is a description of a drug called Filgrastim-ayow, which is a Recombinant Granulocyte Colony Stimulating Factor derived from E. coli. It is available in a single-dose prefilled syringe with a needle guard and is intended for subcutaneous use only. The drug needs to be stored refrigerated in the original carton to protect from light and should not be frozen or shaken. The solution is sterile and has no preservative. The dosage information should be obtained from the prescribing information. The text also includes information about the manufacturer and lot number, but no expiry date is given.*

This is a description of a plunger rod with a safety guard. No further information is available.*

NDC 70121-1568-1 is a prescription drug called Releu ko 300 mcg/0.5 mL. The drug comes in a Single-Dose Prefilled Syringe for subcutaneous use only. The US License No. 2131 identifies it as a product of Amneal Pharmaceuticals LLC. The lot and expiration dates are unreadable.*

This is a description of a pharmaceutical product called "ReleuKo (filgrastim-ayow) Injection" manufactured by Kashiv BioSciences LLC in Piscataway, New Jersey. It is distributed by Amneal Pharmaceuticals LLC in Bridgewater, New Jersey. The product comes in a package of 10 single-dose prefilled syringes with a needle guard, each containing 480 mcg filgrastim-ayow along with other ingredients in 0.8 mL. Details on dosage can be found in the prescribing information.*

Releukod is a sterile solution for subcutaneous injection that contains 480 mcg filgrastim-ayow per 0.8 mL syringe. The solution is derived from E. coli and is a recombinant granulocyte colony stimulating factor. Releukod is prescribed for use under refrigeration between 2°C to 8°C (36°F to 46°F) and it should not be shaken or frozen. It is distributed by Amneal Pharmaceuticals LLC and manufactured by Kashiv BioSciences, LLC. For more information on Releukod's dosage, refer to the prescribing information.*

This is a medication called Filgrastim-ayow injection used to stimulate the production of white blood cells in the body. It comes in a single-dose prefilled syringe with a needle guard and is intended for subcutaneous use only. The medication should be stored in the original carton to protect it from light and refrigerated at 2° to 8°C. This medication should not be frozen or shaken, and the dosage should be determined by a healthcare provider. The manufacturer of this medication is Amneal Pharmaceuticals LLC.*

This is a description for a subcutaneous injection prescription drug named Releu kO 480 mcg/0.8 mL in a single-dose prefilled syringe. The NDC number is 70121-[15] and it is only for Rx use. The expiration date is not available, and the lot number on this injection is not visible. However, it is manufactured by Amneal Pharmaceuticals LG.*

This is a description of a medication named Releuko (filgrastim-ayow) Injection, manufactured by Kashiv BioSciences and distributed by Amneal Pharmaceuticals LLC. The injection contains 300 mcg filgrastim-ayow, acetic acid, polysorbate 80, sodium hydroxide, and sorbitol in water for injection. The dosage information is not available.*

This is a description of a medication with the National Drug Code (NDC) 70121-1569, which is only available with a prescription. The medication is called Releukd and is in the form of an injection in a single-dose vial, containing 300 mcg/mL of filgrastim-ayow. It is intended for subcutaneous or intravenous use only. The manufacturer of the medication is Amneal Pharmaceuticals LLC and the license number is 2131. The lot number and expiration date are provided but not readable in the text.*

This text is a product description for a drug called "filgrastim-ayow" produced by Kashiv BioSciences, LLC. It comes in small 1.6 mL single-dose vials with a 480 mcg dose. The solution contains filgrastim-ayow along with other ingredients in Water for Injection, USP. The dosage instructions can be found in the Prescribing Information. The rest of the text seems to be gibberish and not-available for comprehension.*

This is a prescription medication with the NDC code of 70121-1571. The medication is Releukd 480 mcg/1.6mL injection which is only for subcutaneous or intravenous use. The medication is contained in a single-dose vial. The manufacturer is Amneal Pharmaceuticals LLC and the license number is 21312. The date of revision is 04-2022-01, but the expiration date is not available.*

This text appears to be a list of medical equipment and supplies. It indicates the presence of Sharps, which typically refers to objects that can cause puncture wounds such as needles, syringes or scalpels, and a disposal container for those objects. It also mentions a "Prefilled Syringe," which is a device commonly used to administer medication. Without further context, it's unclear what the purpose of this list is, but it's likely related to managing medical waste or preparing for medical procedures.*

This is a description of recommended injection sites for medication. The text suggests three areas of the body: the stomach area (abdomen), the thigh, and the upper arm. The injection sites are recommended to be on the front or back of the body for maximum efficacy of the injection.*